Copyright © 2019. Inderes Oy. All rights reserved.
BBS
2005 investors follow this company
The company is not covered. See all listed companies from here.
BUY 4.40 LOWEST 4.32 VOLUME 20 016
SELL 4.42 HIGHEST 4.56 VALUE 0,089 Milj. EUR

Would you like to see our recommendations and target prices?

You already have an Inderes account? Log in from here.

Upcoming events

31
Aug
Osavuosikatsaukset

Latest insider trading

Net impact profile

Type: stock_exchange_release
26.6.
2020

The Board of Directors of BBS-Bioactive Bone Substitutes Plc (“BBS” or the “Company”) has learned that in the subscription rights issue decided by the Company's Board of Directors on 26 May 2020, the subscription of 65,500 shares made and paid by one of the Company’s owners, Ahti Paananen, has not been registered, due to an error by Paananen's account manager, in the share allocation approved by the Board of Directors on 24 June 2020.

Type: stock_exchange_release
25.6.
2020


Person subject to the notification requirement
Name: Pekka Jalovaara
Position: Member of the Board/Deputy member
(X) Legal person
Issuer: BBS-Bioactive Bone Substitutes OYJ
LEI: 743700BYSBP0PCR6N767

Notification type: INITIAL NOTIFICATION
Reference number: 743700BYSBP0PCR6N767_20200623141255_9
____________________________________________

Type: stock_exchange_release
24.6.
2020

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, SINGAPORE, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.

Type: stock_exchange_release
12.6.
2020

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, SINGAPORE, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.

Type: stock_exchange_release
29.5.
2020

Company Announcement, Insider Information 29 May 2020 at 11:00 am (UTC +3:00)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, SINGAPORE, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.

Type: stock_exchange_release
26.5.
2020

Company Announcement, 26 May 2020 at 4:00 pm (UTC +3:00)

The Board of Directors of BBS-Bioactive Bone Substitutes Plc has today decided to postpone the Annual General Meeting scheduled for 29 June 2020.

The postponement of the Annual General Meeting will enable new investors who may participate in the rights issue published by the company on May 26 2020, to participate in the Annual General Meeting, thus ensuring equal treatment of shareholders.

Type: stock_exchange_release
26.5.
2020

Company Announcement, Insider information  26 May 2020 at 2:00 pm (UTC +3.00).

The Board of Directors of BBS-Bioactive Bone Substitutes Plc decided on a subscription rights issue and publishes the prospectus and issue terms

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, SINGAPORE, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.

Type: stock_exchange_release
20.5.
2020

Company Announcement, Insider information 20 May 2020 at 01.55 pm. (UTC +3.00)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, SINGAPORE, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.

BBS-Bioactive Bone Substitutes plans to arrange a rights issue of approximately 5.5 MEUR.

Type: stock_exchange_release
9.4.
2020

BBS-Bioactive Bone Substitutes Plc. has published its audited Financial Statements for 2019 at http://www.bbs-artebone.fi/investors/financial-reports/

The Financial Statements is also attached to this release.


BBS-Bioactive Bone Substitutes Plc


More information

Ilkka Kangasniemi, CEO

Type: stock_exchange_release
7.4.
2020

BBS-Bioactive Bone Substitutes Plc’s patent application ”A METHOD FOR PREPARING A BONE PROTEIN PREPARATION AND A BONE PROTEIN PREPARATION” for the product has been accepted in the USA. The company’s product ARTEBONE® is now patented in all countries where it has been applied for. The patent application regarding the production is still in progress in the USA. 


CEO Ilkka Kangasniemi:
”The USA is the most significant market of orthopaedic products. Thus, this news about the patent approval is very remarkable for our company.

BBS

English translation unavailable for BBS.
BBS-Bioactive Bone Substitutes